Format On-demand Duration 9 Hours - 2 Modules Total
This masterclass builds the capability to classify, investigate, and document OOS and OOT events with disciplined scientific reasoning, reducing exposure to inspection findings, product impact decisions, and recurring quality failures while strengthening internal control over laboratory and manufacturing investigations.
Why Take This Course
Out-Of-Specification (OOS) And Out-Of-Trend (OOT) Results Signal Potential Breakdowns In Process Control, Product Quality, And Data Integrity. FDA Expectations Require Structured, Well-Documented Investigations That Distinguish Laboratory Error From True Manufacturing Or Analytical Issues. Inadequate Handling Of These Events Remains A Frequent Source Of Form 483 Observations, Warning Letters, Recalls, And Consent Decrees Across Pharmaceutical, Biotech, Dietary Supplement, And Contract Manufacturing Operations Operating Under CGMP Regulations.
This Course Presents A Detailed Progression From Initial Result Detection Through Classification, Investigation Phases, Root Cause Analysis, Interim Controls, CAPA Development, And Final Reporting. It Clarifies Phase I And Phase II Approaches, Trending Evaluation, Repeat Testing Considerations, And Documentation Standards Expected During Inspection. Real Enforcement Examples Are Used To Reinforce Disciplined Decision-Making And Strengthen Internal Investigation Practices.
Course Agenda
Module 1:
Foundations and Regulatory Framework
FDA definitions and guidance for OOS and OOT
Differences between OOS, OOT, and OOE (Out of Expectation)
Phase I vs Phase II Investigations
Laboratory investigation steps and best practices
Assigning preliminary causes and assessing lab error
Deviation and non-conformance documentation
Real-world OOS case studies
Data integrity risks in OOS handling
Module 2:
Root Cause, CAPA, and Regulatory Expectations
Conducting effective root cause analysis
CAPA development and effectiveness checks
Linkage to batch disposition decisions
Statistical evaluation and OOT trending
Handling repeat results and retesting/averaging
Documentation standards for FDA inspection readiness
Responding to 483s and regulatory expectations for OOS/OOT
Why Strong OOS/OOT Investigations Matter
Effective Handling Of Atypical Results Directly Influences Batch Disposition, Regulatory Exposure, And Overall Quality Credibility. This Course Strengthens Decision-Making Around Investigation Triggers, Retesting Practices, Trending Evaluation, And CAPA Linkage, Helping Organizations Avoid Procedural Gaps That Frequently Surface During FDA Inspections Under CGMP Oversight.
How This Course Structure Builds Investigation Discipline
The Seminar Follows The Natural Progression Of An Atypical Result, Beginning With Regulatory Definitions And Laboratory Assessment Before Advancing To Root Cause Evaluation, Corrective Actions, And Inspection Readiness. Each Stage Builds On The Prior Discussion, Reinforcing Cumulative Reasoning Rather Than Isolated Topics, And Mirroring How Investigations Unfold In Real Operations.
Who Should Attend
Quality Assurance Departments
Quality Control Departments
Manufacturing Departments
Operations Departments
Regulatory Affairs Departments
Compliance Departments
Validation Departments
Technical Services
Auditing/Internal Auditors
Laboratory Analysts
CAPA Coordinators
Site Heads and Directors of Quality
Meredith Crabtree has over 30 years’ experience in regulated industries, ranging from Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. This includes manufacturing, packaging, labelling and distribution operations. Meredith is the owner of MLKC Consulting is s a Quality Consultant specializing in product label reviews, 3rd party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings.